PT  - JOURNAL ARTICLE
AU  - Gómez-López, Alba
AU  - Arismendi, Ebymar
AU  - Cano, Isaac
AU  - Farré, Ramón
AU  - Fígols, María
AU  - Hernández, Carme
AU  - Montilla-Ibarra, Antonio
AU  - Sánchez-Ruano, Núria
AU  - Sánchez, Benigno
AU  - Sisó-Almirall, Antoni
AU  - Sorribes, Marta
AU  - Vela, Emili
AU  - Piera-Jiménez, Jordi
AU  - Benavent, Jaume
AU  - Fermoso, Jose
AU  - Roca, Josep
AU  - González-Colom, Rubèn
TI  - Protocol for the Enhanced Management of Multimorbid Patients with Chronic Pulmonary Diseases: Role of Indoor Air Quality
AID  - 10.1101/2024.05.17.24307036
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.17.24307036
4099  - http://medrxiv.org/content/early/2024/05/17/2024.05.17.24307036.short
4100  - http://medrxiv.org/content/early/2024/05/17/2024.05.17.24307036.full
AB  - Introduction Reducing unplanned hospital admissions in chronic patients at risk is a key area for action due to the high healthcare and societal burden of the phenomenon. The inconclusive results of preventive strategies in patients with chronic respiratory disorders and comorbidities are explainable by multifactorial but actionable factors.The current protocol (January 2024 to December 2025) relies on the hypothesis that intertwined actions in four dimensions: i) management change, ii) personalisation of the interventions based on early detection/treatment of acute episodes and enhanced management of comorbidities, iii) mature digital support, and iv) comprehensive assessment, can effectively overcome most of the limitations shown by previous preventive strategies. Accordingly, the main objective is to implement a novel integrated care preventive service for enhanced management of these patients, as well as to evaluate its potential for value generation.Methods and analysis At the end of 2024, the specifics of the novel service will be defined through the articulation of its four main components: i) Enhanced lung function testing through oscillometry, ii) Continuous monitoring of indoor air quality as a potential triggering factor, iii) Digital support with an adaptive case management approach, and iv) Predictive modelling for early identification and management of exacerbations. During 2025, the novel service will be assessed using a Quintuple Aim approach. Moreover, the Consolidated Framework for Implementation Research will be applied to assess the implementation. The service components will be articulated through four sequential six-months Plan-Do-Study-Act cycles. Each cycle involves a targeted co-creation process following a mixed-methods approach with the active participation of patients, health professionals, managers, and digital experts.Ethics and dissemination The Ethics Committee for Human Research at Hospital Clinic de Barcelona approved the protocol on June 29, 2023 (HCB/2023/0126). Before any procedure, all patients in the study must sign an informed consent form.Registration NCT06421402.STRENGTHS AND LIMITATIONSThe articulation of the four service components, identified in a previous co-creation process, ensures a comprehensive approach to the novel integrated care service.Innovative features of the digital support to the service provided by the Health Circuit platform, based on an Adaptive Case Management orientation, should contribute to overcoming current limitations in digital health transformation.Using a Plan-Do-Study-Act strategy, with targeted objectives for each co-creation cycle, will ensure the maturity of the service design and evaluation processes throughout the protocol’s execution.The comprehensive evaluation of the novel service, including a Quintuple Aim approach and assessment of the deployment process using the Consolidated Framework for Implementation Research, will contribute to overcoming the efficacy-effectiveness gap seen in this type of integrated care service.A potential constraint is that only some patients within the cohort may qualify as future candidates for the innovative service in an actual working environment. Nonetheless, the established protocol is designed to effectively discern and identify the specific patient profiles who stand to derive notable benefits from these interventions.Competing Interest StatementIsaac Cano and Josep Roca hold shares of Health Circuit. All other authors declare no conflicts of interest.Clinical TrialNCT06421402Funding StatementThe K-HEALTHinAIR project funded this study, Grant Agreement number 101057693, under a European Union Call on Environment and Health (HORIZON-HLTH-2021-ENVHLTH-02). Disclaimer: Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency as granting authority. Neither the European Union nor the granting authority can be held responsible. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethical Committee for Human Research at Hospital Clinic de Barcelona approved the core study protocol of K-Health in Air on June 29, 2023 (HCB/2023/0126). The study design adheres to data minimisation principles, ensuring that only essential data are collected and utilised. The study will be conducted in compliance with the Helsinki Declaration (Stronghold Version, Brazil, October 2013) and in accordance with the protocol and the relevant legal requirements (Biomedical Research Act 14/2007 of July 3). All patients in the study must sign an informed consent form before any procedure. The participants can withdraw their consent at any time without altering their relationship with their doctor or harming their treatment. The One Beat watch does not hold medical device certification and will be utilized solely for data collection and exploring potential patterns informing exacerbations, not for decision-making within the study. Any future application derived from this research must ensure that the technology aligns with medical device regulations. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData availability does not apply to this article since it describes a protocol rather than presenting study resultsAISBEIntegrated Health District of Barcelona-EsquerraACTAsthma Control TestAQLQAsthma Quality of Life QuestionnaireALDSAmbulatory Lung Diagnosis SystemAMGAdjusted Morbidity GroupsCATCOPD Assessment testCFIRConsolidated Framework for Implementation ResearchCOPDChronic Obstructive Pulmonary DiseaseFSForced SpirometryHCBHospital Clínic de BarcelonaHRVHeart Rate VariabilityICHOMInternational Consortium for Health Outcomes ManagementIAQIndoor Air QualityK-HEALTHinAIREU Project “Knowledge for improving indoor AIR quality and HEALTH”mMRCmodified Medical Research CouncilNPSNet Promoter ScorePaRISPatient-Reported Indicator SurveyPMParticulate MatterPROMISPatient-Reported Outcomes Measurement Information SystemPROMsPatient-Reported Outcome MeasuresPDSAPlan-Do-Study-Act cyclePREMsPatient-Reported Experience MeasuresPSPropensity Score MatchingSUSSystem Usability ScaleSNOTSino-Nasal Outcome TestTAITest of Adherence to InhalersVOCVolatile Organic CompoundWHOWorld Health Organization